Inventor
BHAGWAT SHRIPAD S
US35 patents
⚠️ This page may combine multiple inventors who share the name “BHAGWAT SHRIPAD S”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SIGNAL PHARM LLC
10 patentsUS7129242B2Oct 31, 2006
Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
SIGNAL PHARM LLC59 citations96
US7220771B2May 22, 2007
Methods of using indazole derivatives as JNK inhibitors
SIGNAL PHARM LLC22 citations91
US7211594B2May 1, 2007
Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
SIGNAL PHARM LLC23 citations91
US7208513B2Apr 24, 2007
Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
SIGNAL PHARM LLC16 citations91
US7122544B2Oct 17, 2006
Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
SIGNAL PHARM LLC20 citations90
US7429599B2Sep 30, 2008
Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
SIGNAL PHARM LLC12 citations84
US7442699B2Oct 28, 2008
Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
SIGNAL PHARM LLC10 citations82
US7119114B1Oct 10, 2006
Pyrazoloanthrone and derivatives thereof as JNK inhibitors and compositions and methods related thereto
SIGNAL PHARM LLC16 citations81
US7279489B2Oct 9, 2007
Compounds and methods for modulation of estrogen receptors
SIGNAL PHARM LLC0 citations51
US7335676B2Feb 26, 2008
Methods for treating inflammatory conditions or inhibiting JNK
SIGNAL PHARM LLC0 citations49
SIGNAL PHARM INC
8 patentsUS6897231B2May 24, 2005
Indazole derivatives as JNK inhibitors and compositions and methods related thereto
SIGNAL PHARM INC62 citations95
US6331562B1Dec 18, 2001
Compounds and methods for modulation of estrogen receptors
SIGNAL PHARM INC63 citations94
US6291456B1Sep 18, 2001
Compounds and methods for modulation of estrogen receptors
SIGNAL PHARM INC62 citations93
US6686351B2Feb 3, 2004
Compounds and methods for modulation of estrogen receptors
SIGNAL PHARM INC15 citations91
US6620838B1Sep 16, 2003
Benzopyrazone compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM INC24 citations91
US6436923B1Aug 20, 2002
Compounds and methods for modulation of estrogen receptors
SIGNAL PHARM INC26 citations91
US6593322B1Jul 15, 2003
Compounds and methods for modulation of estrogen receptors
SIGNAL PHARM INC31 citations90
US6372739B1Apr 16, 2002
Compounds and methods for modulation of estrogen receptors
SIGNAL PHARM INC13 citations71
AMBIT BIOSCIENCES CORP
5 patentsUS9320739B2Apr 26, 2016
RAF kinase modulator compounds and methods of use thereof
AMBIT BIOSCIENCES CORP6 citations83
US8969587B2Mar 3, 2015
RAF kinase modulator compounds and methods of use thereof
AMBIT BIOSCIENCES CORP8 citations83
US10053430B2Aug 21, 2018
RAF kinase modulator compounds and methods of use thereof
AMBIT BIOSCIENCES CORP1 citations62
US9730937B2Aug 15, 2017
RAF kinase modulator compounds and methods of use thereof
AMBIT BIOSCIENCES CORP1 citations62
US9585892B2Mar 7, 2017
Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith
AMBIT BIOSCIENCES CORP1 citations49
CIBA GEIGY CORP
3 patentsUS5670497ASep 23, 1997
Cyclic hydrazine compounds
CIBA GEIGY CORP66 citations96
US5025025AJun 18, 1991
(Arylsulfonamido- and pyridyl-)-substituted carboxylic acids and derivatives thereof and use for suppressing thromboxane activity
CIBA GEIGY CORP12 citations70
US5153214AOct 6, 1992
Certain (arylsulfonamido- and imidazolyl-)-substituted carboxylic acids and derivatives thereof and use for suppressing thromboxane activity
CIBA GEIGY CORP1 citations48